Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9472
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa |
Author: | Klinkenberg-Knol, E. Nelis, F. Dent, J. Snel, P. Mitchell, B. Prichard, P. Lloyd, D. Havu, N. Frame, M. Roman, J. Walan, A. |
Citation: | Gastroenterology, 2000; 118(4):661-669 |
Publisher: | W B Saunders Co |
Issue Date: | 2000 |
ISSN: | 0016-5085 1528-0012 |
Abstract: | <h4>Background & aims</h4>The efficacy and safety of long-term acid suppression remains a subject for debate. We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6.5 years (range, 1.4-11.2 years).<h4>Methods</h4>Patients with severe reflux esophagitis resistant to long-term therapy with H(2)-receptor antagonists and who were not eligible for surgery were evaluated at least annually for endoscopic relapse and histological changes in the gastric corpus.<h4>Results</h4>In 230 patients (mean age, 63 years at entry; 36% were >/=70 years), there were 158 relapses of esophagitis during 1490 treatment years (1 per 9.4 years), with no significant difference in relapse rates between Helicobacter pylori-positive and -negative patients. All patients rehealed during continued therapy with omeprazole at the same or higher dose. The annual incidence of gastric corpus mucosal atrophy was 4.7% and 0.7% in H. pylori-positive and -negative patients, respectively, which was mainly observed in elderly patients who had moderate/severe gastritis at entry. In patients with baseline moderate/severe gastritis, the incidences were similar: 7.9% and 8.4%, respectively. Corpus intestinal metaplasia was rare, and no dysplasia or neoplasms were observed. The adverse event profile was as might be expected from this elderly group of patients.<h4>Conclusions</h4>Long-term omeprazole therapy (up to 11 years) is highly effective and safe for control of reflux esophagitis. |
Keywords: | Long-Term Study Group Gastric Mucosa Humans Helicobacter Infections Barrett Esophagus Gastroesophageal Reflux Esophagitis Gastritis Hyperplasia Omeprazole Gastrins Anti-Ulcer Agents Treatment Outcome Drug Resistance Time Factors Adolescent Adult Aged Aged, 80 and over Middle Aged Child Female Male |
DOI: | 10.1016/S0016-5085(00)70135-1 |
Published version: | http://dx.doi.org/10.1016/s0016-5085(00)70135-1 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.